© 2024 MJH Life Sciences™ , Cannabis Science and Technology . All rights reserved.
Jazz Pharmaceuticals revealed that presentations taking place at the 2023 American Epilepsy Society (AES) annual meeting will include long-term and real-world data about treatment-resistant epilepsy.
Taking place at the 2023 American Epilepsy Society (AES) annual meeting, Jazz Pharmaceuticals, a global biopharmaceutical company, disclosed that there will be nine company-sponsored presentations which include five late-breaking abstracts covering Epidiolex® data in a recent press release (1). The meeting will be taking place in Orlando, Florida, on December 1-5, 2023.
Epidiolex® (cannabidiol [CBD]) is a drug used for treatment-resistant epilepsy such as those seen in patients who have Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) (1). Presentations at AES will showcase long-term and real-world results from the Expanded Access Program (EAP), GWPCARE6 Open-Label Extension (OLE) trial, the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) (tuberous sclerosis complex [TSC]), and more (1).
"Multiple presentations at the 2023 AES meeting continue to build the scientific evidence in support of Epidiolex and improve understanding around the treatment's full impact," Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals mentioned (1). "In addition to seizure outcomes, the BECOME studies are also designed to assess non-seizure benefits of Epidiolex, such as cognition and executive function, emotional and social function, and language and communication. We are determined to not only address seizure outcomes for patients living with rare epilepsies, but also improve the day-to-day lives for both patients and their loved ones."
In Jazz Pharmaceuticals press release, they announced a few of the data highlights which will be shared during the meeting (1):
To view the AES abstracts, please visit (2): https://aesnet.org/education/annual-meeting/aes-abstract-search.
References